Dilated cardiomyopathy (DCMP), the leading type of cardiomyopathy in children, can be either a primary disease or secondary to a host of pathologies. Endocrine diseases are an extremely rare cause of DCMP in children.
Introduction
H ypopituitarism is defi ned as absence or reduction in function of two or more hormones produced by the pituitary gland 1 . It affects 1 in 4000 to 1 in 10,000 live births, with incidence increasing with age 2 . Congenital hypopituitarism may present in a variety of phenotypes depending on the hormonal defi ciency (partial vs. pan hypopituitarism) and associated developmental defects 1, 2 . Dilated cardiomyopathy (DCMP) is the leading cause of cardiomyopathy in both adults and children with a poor long term prognosis 3 . DCMP is a rare condition with an incidence of 0.56-1.24/ 100,000 children per year; boys and infants being affected more commonly 3, 4 . It can be either a primary condition or secondary to a host of secondary causes with the commonest recognizable cause being myocarditis 3 . Endocrinologic causes of DCMP are extremely rare in children; mostly associated with thyroid dysfunction 5 . Among the adults also, metabolic causes constituted only 1.5% of cases, again, mostly due to thyroid disorders 6 . We report a 10 years old boy with hypopituitarism and DCMP presenting with cardiac failure.
The Case
A-10-year-old boy presented with complaints of insidious onset, gradually progressive dyspnoea and orthopnoea for six months.
There was also history of abdominal distension, pedal oedema, easy fatigability, constipation, noisy breathing and somnolence. The child was 1 st born to a nonconsanguineously married couple. He was born at term by normal vaginal delivery at home with apparently normal birth weight. There was history of delayed cry at birth requiring stimulation. He had feeding diffi culty and failure to thrive since beginning and also had global developmental delay with cognition affected more than the motor and language domains. There was no history of palpitation, black out, jaundice, decreased urine output, seizure, altered sensorium, bleeding from any site or requirement for blood transfusion. There were four younger apparently normal male and female siblings and no history of abortion in the mother or early infantile death in the family. There was no similar history in the family. He consumed 1100 kcal and 19 gm protein per day.
On examination, the child was lethargic with cold peripheries, heart rate 100/ min, all peripheral pulses well palpable, capillary fi lling time <3 seconds, BP 116/ 70 mmHg. He had marked respiratory distress with tachypnoea (respiratory rate 36/min), chest retractions and intermittent stridor. There was hypoxemia evident by central cyanosis and Spo2 of 80% in room air. Anthropometry revealed short stature (height 75 cm, <-3 SD), with upper: lower segment ratio 42: 33, underweight (10 kg, <-3 SD), and microcephaly (head circumference 46 cm, <-3 SD). General physical examination revealed, moderate pallor, pitting pedal oedema, dry scaly skin, pot belly, frontal bossing, saddle nose, macro-glossia, low set ears, sparse hair and anterior fontanel was still open (Figure 1a ). There was evidence of delayed dentition as well. His sexual maturity was at Tanner's stage 1. Systemic examination was remarkable with presence of ascites, hepatomegaly, and crepitation on auscultation of both lungs and a Grade-3 ejection systolic murmur without any S3 gallop.
Investigations revealed bone age <1 year ( Figure  1b) , microcytic, hypochromic anaemia, markedly elevated serum alkaline phosphatase, and recurrent episodes of asymptomatic hypoglycaemia (Table 1) . Chest x-ray showed massive cardiomegaly ( Figure  1c ) and echocardiography confi rmed dilated ventricles with tricuspid and mitral regurgitation, biventricular dysfunction (ejection fraction 45%) and pericardial effusion (8 mm) but no evidence of tamponade. He was started on moist O2 inhalation, diuretic (Frusemide) and Digoxin with improvement in symptoms. Further investigations were suggestive of hypopituitarism with central hypothyroidism, hypoprolactinaemia, hypocortisolism (Table 1 ) and growth hormone (GH) defi ciency (GH on GH stimulation test: at 0 hourundetectable, at 30 minutes-undetectable, at 60 mins-0.1 ng/ml, at 120 mins-0.2 ng/ml). Water deprivation test could not be done in view of the critical condition of the patient and diuretic therapy.
Thyroxine (at a dose of 5 mcg/kg/day), growth hormone (Recombinant growth hormone @ 0.25 IU/Kg/ week) and hydrocortisone (at a dose of 10 mg/m 2 /day) supplementation was started. MRI (Magnetic resonance imaging) of brain could not be done in view of the child's poor general condition and facilities for genetic studies for known mutations of hypopituitarism were not available at our centre. With further symptomatic improvement, the parents took the child home against medical advice and he was lost to follow up. 
Discussion
We present a paediatric case of hypopituitarism leading to DCMP and cardiac failure. DCMP secondary to hypopituitarism leading to cardiac failure has been reported both in adults 7 and newborn 8 . But, to the best of our knowledge, no such case has reported in the pediatric age group in the English literature before.
Cardiomyopathy associated with hypopituitarism may be attributed to GH 9 , glucocorticoid 10 and thyroid 11 Creatinine (mg/dl) 0.6 Prolactin (ng/ml) 0.05 (normal 0.9-12.9)
Uric acid (mg/dl) 5. defi ciency. GH is a physiological regulator of myocardial growth and performance. Cardiac growth and function are impaired in children with congenital GH defi ciency. In these cases, administration of GH leads to increase in wall thickness and normalization of cardiac performance which also reverses upon stopping the treatment 12 . Thyroid hormones, principally T3 (Tri-iodothyronine), exerts its actions on the cardiovascular system by its genomic modifi cation over cardiac myocytes and extranuclear nongenomic effects on both myocyte and on the systemic vasculature. The mechanisms through which hypothyroidism can lead to heart failure includes: bradycardia, impaired systolic function, impaired left ventricular diastolic fi lling, increased systemic vascular resistance, diastolic hypertension, increased arterial stiffness and endothelial dysfunction. Both experimental and clinical studies have demonstrated thyroid hormone supplementation to reduce myocyte apoptosis and consequently improve cardiovascular performance and ventricular remodeling 13 .
The pituitary dysfunction in our case seemed to be congenital, as the child was symptomatic since the very beginning with poor growth along with severely retarded bone maturation, presence of micro phallus and absence of any history suggestive of secondary causes of hypopituitarism (e.g. head trauma, surgery, neuro-infection, cranial radiation, etc.) 1,2 . We could not perform a water deprivation test to assess antidiuretic hormone (ADH) function; therefore, it remained unclear, whether it was a case of pan hypopituitarism or partial hypopituitarism. Though, historically, there was no polyuria suggesting ADH defi ciency. Genetic testing could not be performed in our case to fi nd the known mutations associated with hypopituitarism; however, the child also did not have any features (such as midline defects, visual disturbances, etc) to suggest a genetic defect. We started GH, corticosteroid and thyroid replacement together as it was found to be safe and effective in both adult and neonate previously 7, 8 but unfortunately, we could not follow the child to demonstrate their long term effect on the cardiovascular function.
Conclusion
We appreciate that association of hypopituitarism with DCMP in this case may not necessarily imply causal association. But the available literature does suggest that hypopituitarism may present with DCMP and respond favourably to a combination of hormonal replacement therapy along with standard therapy for CCF.
